For research use only. Not for therapeutic Use.
Bromoacetamido-PEG4-acid（Cat No.:I016457） is a versatile PROTAC linker belonging to the PEG (polyethylene glycol) class. It is employed in the synthesis of PROTAC molecules, which are designed to selectively target and degrade specific proteins of interest. Additionally, Bromoacetamido-PEG4-acid serves as a cleavable ADC (antibody-drug conjugate) linker. It contains four units of PEG and enables the conjugation of therapeutic drugs to antibodies, facilitating the development of targeted ADCs for improved drug delivery and efficacy in various diseases, particularly cancer.
| Catalog Number | I016457 |
| CAS Number | 1807518-67-7 |
| Molecular Formula | C₁₃H₂₄BrNO₇ |
| Purity | ≥95% |
| Target | Antibody-drug Conjugate/ADC Related |
| IUPAC Name | 3-[2-[2-[2-[2-[(2-bromoacetyl)amino]ethoxy]ethoxy]ethoxy]ethoxy]propanoic acid |
| InChI | InChI=1S/C13H24BrNO7/c14-11-12(16)15-2-4-20-6-8-22-10-9-21-7-5-19-3-1-13(17)18/h1-11H2,(H,15,16)(H,17,18) |
| InChIKey | LMFYGPXSVUULRZ-UHFFFAOYSA-N |
| SMILES | C(COCCOCCOCCOCCNC(=O)CBr)C(=O)O |
| Reference | [1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562.<br>[2]. Beck A, et al. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017 May;16(5):315-337. |
